Event Abstract Back to Event Clausenidin suppresses the production of VEGF and inhibits angiogenesis of HepG2 cells Peter M. Waziri1*, Rasedee Abdullah2, Kartinee N. Kassim3 and Jaafar M. Sani4 1 Kaduna State University, Nigeria 2 Faculty of Veterinary Medicine, Putra Malaysia University, Malaysia 3 Faculty of Science, Putra Malaysia University, Malaysia 4 Universiti Putra Malaysia, Malaysia Background Metastasis of tumor cells is responsible for over 90% of cancer deaths globally. The production of vascular endothelial growth factor (VEGF) promotes metastasis and immortality of cancer cells. Up till date, there is still no clinical drug that effectively prevents the production of VEGF in tumor cells. Clausena excavata Burm. f (local name: cherek hitam) is a shrub that is used locally for the treatment of cancer tumors in Malaysia and other countries of South East Asia. The current study evaluated the effect of clausenidin isolated from the chloroform extract of C. excavata on the production of VEGF in liver cancer (HepG2) cells. Methods The anti-angiogenic effect (production of VEGF) in the clausenidin-treated cells was monitored using Western blot assay and the anti-apoptotic effect of the pure compound was monitored using transmission electron microscopy (TEM). Prior to Western blot analysis, the cells were treated with 5, 15, 30 and 40 µg/mL of clausenidin and in the TEM analysis, cells were treated with the IC50 (7.7 µg/mL) of clausenidin at 24, 48 and 72 h. Results The Western blot analysis showed that clausenidin treatment significantly reduced (p<0.05) the production of VEGF that causes metastasis of liver cancer cells in a dose-dependent manner. In addition, we observed apoptosis to be one of the routes of cell death in the clausenidin-treated cells. The TEM analysis revealed margination and condensation of chromatin, nuclear fragmentation, formation of lipid droplets and convolution of nuclear outline (at all treatment points) which confirmed apoptosis of the clausenidin-treated HepG2 cells. Conclusion Clausenidin can be used as an anti-angiogenic and anti-apoptotic agent for the treatment of liver cancer. Acknowledgements The authors are grateful to MAKNA Cancer Research Laboratory, Institute of Bioscience, Universiti Putra Malaysia. Keywords: Clausenidin, VEGF, Apoptosis, Angiogenesis, Cancer Conference: International Conference on Drug Discovery and Translational Medicine 2018 (ICDDTM '18) “Seizing Opportunities and Addressing Challenges of Precision Medicine”, Putrajaya, Malaysia, 3 Dec - 5 Feb, 2019. Presentation Type: Oral Presentation Topic: Cancer Citation: Waziri PM, Abdullah R, Kassim KN and Sani JM (2019). Clausenidin suppresses the production of VEGF and inhibits angiogenesis of HepG2 cells. Front. Pharmacol. Conference Abstract: International Conference on Drug Discovery and Translational Medicine 2018 (ICDDTM '18) “Seizing Opportunities and Addressing Challenges of Precision Medicine”. doi: 10.3389/conf.fphar.2018.63.00118 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 29 Nov 2018; Published Online: 17 Jan 2019. * Correspondence: Dr. Peter M Waziri, Kaduna State University, Kaduna, Nigeria, petermwaziri@gmail.com Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Peter M Waziri Rasedee Abdullah Kartinee N Kassim Jaafar M Sani Google Peter M Waziri Rasedee Abdullah Kartinee N Kassim Jaafar M Sani Google Scholar Peter M Waziri Rasedee Abdullah Kartinee N Kassim Jaafar M Sani PubMed Peter M Waziri Rasedee Abdullah Kartinee N Kassim Jaafar M Sani Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.
Read full abstract